Figure 2.

Cox proportional hazard model to estimate the rates of discontinuation according to CYP2C19 phenotype (Hazard Ratio = 0.432 for each incremental change in phenotype, 95% Confidence Interval 0.237 to 0.790, P = 0.006 after adjustment for current leflunomide dose, continuation of triple therapy and positive rheumatoid factor at diagnosis).

Wiese et al. Arthritis Research & Therapy 2012 14:R163   doi:10.1186/ar3911
Download authors' original image